Topic: Heart Failure

Hypertrophic Cardiomyopathy

Oct 2021 | Assessment

Interventions of Interest: mavacamten (Camzyos™, MyoKardia and Bristol-Myers Squibb) Concerns about long-term safety influenced majority of independent appraisal committee to vote that evidence is not currently adequate to demonstrate a net health benefit of mavacamten added to background therapy. Using estimates from modeling of short-term benefits, mavacamten does show an overall benefit but would have […]

Congestive Heart Failure

Nov 2015 | Assessment

Interventions of interest: CardioMEMS™ HF System (St. Jude Medical) Sacubitril/valsartan (Entresto™, Novartis) Congestive heart failure (CHF) describes the condition of fluid build-up in the body as the heart inefficiently fills with or pumps out blood. CHF results from other conditions that weaken the heart muscle including coronary artery disease, myocardial infarction, cardiomyopathy, and hypertension, and […]